A multimillion dollar research partnership announced today at the University of Alberta is giving a “dream team” of researchers the opportunity to potentially transform cancer treatment and better patient outcomes.
Alberta Cancer Foundation and BioCanRx are pleased to invite the public and the media to public symposia in both Edmonton and Calgary on lmmunotherapy, a new type of cancer treatment that boosts the body’s natural defenses to fight cancer. The goal of these events is to bring together Albertans and the brightest Canadian minds in lmmunotherapy to talk about emerging research in the area of cancer diagnosis and treatment. As well, patients will share their stories and the impact that has already been made right here at home.
Alberta Innovates, the Alberta Cancer Foundation and DynaLIFE have joined together to help commercialize Alberta-owned innovations that will detect cancer earlier and improve treatment for Albertans. The challenge was part of Alberta Innovates’ Alberta Small Business Innovation and Research Initiative (ASBIRI) program and included insight from Alberta Health Services.
For 50 years, the Cross Cancer Institute has been delivering world-class treatment and care to Albertans facing cancer. A passionate group of community business leaders has come together to celebrate this facility by launching a lofty fundraising campaign that will continue to support the Cross Cancer Institute for years to come.
Each year, thousands of Canadian men with prostate cancer undergo biopsies to help their doctors better understand the progression and nature of their disease. It provides vital, sometimes life-saving information, yet cancer researcher John Lewis knows it can be a difficult test to ask of anyone.
Heart medication taken in combination with chemotherapy reduces the risk of serious cardiovascular damage in patients with early-stage breast cancer, according to results from a new landmark clinical trial.Existing research has shown some cancer therapies such as Herceptin greatly improve survival rates for early-stage breast cancer, but come with a fivefold risk of heart failure—a devastating condition as life-threatening as the cancer itself.
Researchers in Calgary and Edmonton have launched a lung cancer screening study to determine the best criteria for catching the deadly disease while it’s still treatable.
The Alberta Cancer Foundation has invested $3 million into a colorectal research projectthat will prevent tumours from being able to repair themselves after radiation treatment, increasing the chance of success for patients facing this disease.
In honour of International Clinical Trials Day, please consider making a gift that will help double our capacity for life-saving clinical trials at the Cross Cancer Institute.
